Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Jacksonville, Florida

CNS medication trials in Jacksonville, FL

30 CNS medication studies are recruiting participants at sites in Jacksonville as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Jacksonville at a glance

  • 30 studies are recruiting at a site in Jacksonville.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (1), Phase 2 (12), Phase 3 (12), Phase 4 (3).
  • By sponsor: industry (27), university, hospital or other (3).
  • By research area: Depression (13), ADHD (5), Epilepsy (4), Parkinson's Disease (3), Migraine (2), Multiple Sclerosis (2), Schizophrenia (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Jacksonville

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigator Site
    Registry record
    NCT07901179 · updated
  2. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    CNS Healthcare - Jacksonville
    Registry record
    NCT07226661 · updated
  3. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    CNS Healthcare
    Registry record
    NCT06793397 · updated
  4. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  5. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Clinical Neuroscience Solutions, LLC (Jacksonville)
    Registry record
    NCT07592689 · updated
  6. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  7. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  8. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  9. Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

    • Phase 2
    • Ages 18 to 99
    • All sexes
    Sponsor
    Hospital Italiano de Buenos Aires
    Study site
    Mayo Clinic
    Registry record
    NCT07639359 · updated
  10. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Syndeio Biosciences, Inc
    Study site
    Clinical Neuroscience Solutions, Inc.
    Registry record
    NCT06547489 · updated
  11. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Cns Healthcare - Jacksonville /ID# 277658
    Registry record
    NCT07276997 · updated
  12. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #101
    Registry record
    NCT06633016 · updated
  13. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT06223880 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Jacksonville

  1. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Green Leaf Clinical Trials
    Registry record
    NCT06229210 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Jacksonville, FL on ClinicalTrials.gov.

ADHD studies recruiting in Jacksonville

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
    Registry record
    NCT07759154 · updated
  4. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated
  5. Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

    • Phase 4
    • From 48 months, up to 69 months
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Clinical Neuroscience Solutions, Inc.
    Registry record
    NCT04781140 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Jacksonville

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic Hospital ( Site 0013)
    Registry record
    NCT06966700 · updated
  2. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
    Registry record
    NCT06170788 · updated
  3. Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Ashvattha Therapeutics, Inc.
    Study site
    Mayo Clinic Jacksonville
    Registry record
    NCT05395624 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Jacksonville

  1. PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    PhenoNet, Inc.
    Study site
    Mayo Clinic Jacksonville
    Registry record
    NCT07142291 · updated
  2. AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amylyx Pharmaceuticals Inc.
    Study site
    Mayo Clinic in Florida
    Registry record
    NCT06665165 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Epilepsy studies recruiting in Jacksonville

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT05667142 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Mayo Clinic Florida
    Registry record
    NCT05716100 · updated
  3. Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

    • Early Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic
    Registry record
    NCT07012148 · updated
  4. Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Green Leaf Clinical Trials, LLC
    Registry record
    NCT05518578 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Migraine studies recruiting in Jacksonville

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic Florida
    Registry record
    NCT06972056 · updated
  2. A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

    • Phase 3
    • Ages 18 to 45
    • Female participants
    Sponsor
    Pfizer
    Study site
    Jacksonville Center for Clinical Research
    Registry record
    NCT06641466 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Jacksonville, FL on ClinicalTrials.gov.

Ask about studies near Jacksonville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call